FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
TriSalus Life Sciences, Inc. Stock AnalysisComprehensive stock analysis for TriSalus Life Sciences, Inc. (TLSI) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisTLSI
TLSI
TriSalus Life Sciences, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
TLSI
Home🔹Stocks🔹TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc.

TLSI•NASDAQ

TriSalus Life Sciences, Inc.

TLSI•NASDAQ
Market cap
$164.15M
Sentiment

Your view on TLSI

Mkt Cap
$164.15M
Sentiment
Your view
TLSI
TriSalus Life Sciences, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
TLSI
Company Overview

Overview

What the company does, where it operates, and who runs it.

About TriSalus Life Sciences, Inc.

Industry
Medical - Devices
Sector
Healthcare
CEO
Mary T. Szela B.S.N.,
Headquarters
6272 West 91st Avenue, Westminster, CO, US
Industry
Medical - Devices
Sector
Healthcare
CEO
Mary T. Szela B.S.N.,
Headquarters
6272 West 91st Avenue, Westminster, CO, US
Description

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News